Skip to main content
Independent federal grant matching. Not affiliated with any government agency. Get free access and see which open grants fit your organization.
Closed on Oct 9, 2026

Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)

National Institutes of Health · Opportunity number RFA-DK-27-121

Details summarized from the official notice as of Oct 10, 2026. Always confirm eligibility, deadlines and requirements in the official notice before applying.

Independent platform. Not affiliated with or endorsed by any government agency. Data from public federal sources.

This opportunity is closed as of Oct 9, 2026. It is kept here for reference. See the related open opportunities below, or check the official listing in case the agency posts a new cycle.

Key facts

Opportunity numberRFA-DK-27-121
AgencyNational Institutes of Health
Department of Health and Human Services
Assistance listing (ALN, formerly CFDA)93.847
PostedJun 8, 2026
DeadlineOct 9, 2026
Expected number of awards1
Estimated total program funding$1,000,000
Cost sharing or matching requiredNo
Funding typeCooperative agreement
CategoryHealth
Last updated hereOct 10, 2026

Summary from the notice

This Notice of Funding Opportunity (NOFO) invites applications for a Research Coordinating Center (RCC) to participate in a consortium of clinical centers that will test anti-obesity medication (AOM) treatment strategies for youth with obesity that maximize benefits and minimize risks of AOM use. Such intervention strategies should support the promotion of healthy growth and development; adequate nutritional status/intake, healthy eating and physical activity behaviors; mental health and well-being (e.g., body image, self-esteem, mood, etc.), and quality of life and be feasible to implement in clinical care settings. Priority areas include testing strategies to determine optimal developmental stage for AOM initiation, rate and amount of weight loss, AOM class, dose, frequency, and duration, and content and intensity of adjunct lifestyle therapies that may be imperative to ensure normal psychological and physical development and to potentially avoid lifelong dependence on AOMs. Investigators should also evaluate potential predictors of response/ nonresponse to various treatment strategies under evaluation. The clinical centers may conduct independent or multicenter trials but will collaborate on the development of protocols, use of common measures and data elements, use of a central laboratory and standardized procedures to collect data and biospecimens, and data analyses and manuscriptsThe RCC will lead, manage, and harmonize efforts for the Consortium including 1) providing management and administrative support; 2) providing leadership and expertise on statistical design and analysis, 3) providing research coordination with a central laboratory, 4) harmonizing data collection methods and use of common data elements, 5) developing the database; 6) conducting data management and data analyses for Consortium studies; and 7) fostering research collaborations. This NOFO uses a cooperative agreement mechanism (U24) and runs in parallel with a companion NOFO (RFA-DK-27-121).

Who can apply

The official notice lists these applicant types as eligible:

  • Independent school districts
  • For-profit organizations other than small businesses
  • State governments
  • County governments
  • Federally recognized tribal governments
  • Other Native American tribal organizations
  • Nonprofits with 501(c)(3) status (other than colleges)
  • Small businesses
  • Others named in the notice (see the eligibility text)
  • Private colleges and universities
  • Special district governments
  • Public and Indian housing authorities
  • City or township governments
  • Public and state colleges and universities
  • Nonprofits without 501(c)(3) status (other than colleges)

Who should take a closer look

  • Small businesses
  • Nonprofits
  • Colleges and universities
  • State governments
  • Local governments
  • Tribal governments and organizations
  • Larger for-profit companies

Not listed as eligible

  • Individuals

Unless the eligibility text in the notice names you, this opportunity is probably not for you.

Eligibility details from the notice

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Registrations you will likely need

Most applications submitted through Grants.gov need the following. Registration can take several weeks, so start early. The notice lists the exact requirements.

Related open opportunities

Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)

National Institutes of Health · PAR-25-155

Deadline: Oct 19, 2026 (3 days left) Up to: $50,000 Health

Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-021

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

National Institutes of Health · RFA-CA-27-020

Deadline: Oct 19, 2026 (3 days left) Up to: $600,000 Health